NCT04754321View on ClinicalTrials.gov

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Head and Neck Carcinoma of Unknown PrimaryLocally Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell CarcinomaRecurrent Pharyngeal Squamous Cell CarcinomaResectable Head and Neck Squamous Cell Carcinoma
Interventions
RADIATION

External Beam Radiation Therapy

Undergo EBRT

RADIATION

Intraoperative Radiation Therapy

Undergo IORT

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

PROCEDURE

Salvage Surgery

Undergo salvage surgery

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER